Tasimelteon Oral Suspension

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Insomnia Disorder

Drug Information

Target Indication

Insomnia Disorder

Clinical Trial

Last updated: 1/12/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA7/3/2015

Hetlioz

Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.

Drug Science

Mechanism of action & safety profile

Developer

VNDA

Vanda Pharmaceuticals Inc.

Related Pipeline

Motion Sickness

Insomnia

Primary Insomnia

Moderate-to-severe Chronic Plaque Psoriasis

Autism Spectrum Disorder

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts